|
| Status |
Public on Sep 11, 2013 |
| Title |
PB_male_15day_rep4PB_G62M_D15_4 |
| Sample type |
RNA |
| |
|
| Source name |
Phenobarbital, male mice, 15 days
|
| Organism |
Mus musculus |
| Characteristics |
gender: male
strain: CD-1 mouse
tissue: Liver
treatment: Phenobarbital
time: 15 days
|
| Treatment protocol |
After 3 and 14 days of compound treatment mice were anaesthetized in isoflurane and exsanguinated from the heart and subjected to necropsy. The left lateral liver lobe was extracted and snap frozen under -80°C conditions.
|
| Growth protocol |
CD-1 male and female mice were orally treated with a set of genotoxic carcinogens (CIDB, DMN and MDA), nongenotoxic carcinogens (DCB, PB and PBO), non-hepatocarcinogens (CFX, Nif, Praz and Prop) and a group of undefined compounds (CPA, Wy-14643 and TAA) over a period of 3 and 14 days.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Liver tissue was homogenized and RNA isolation was performed with Qiazol extraction (Qiagen, Hilden,Germany).
|
| Label |
biotin
|
| Label protocol |
Labeling according to 3'IVT Express Kit User Manual Affymetrix
|
| |
|
| Hybridization protocol |
cRNA synthesis, target hybridization, washing, staining and subsequent probe array scanning was done according to the manufacturer's instructions (3'IVT Express Kit User Manual Affymetrix)
|
| Scan protocol |
Scanner 3000 7G; Software GCOS (Genechip Operating Software) version 1.4.0
|
| Description |
Gene expression data from liver samples of male CD1 mice treated with Phenobarbital up to 15 days.
|
| Data processing |
The raw microarray data was normalized using the RMA method implemented in R/Bioconductor.
|
| |
|
| Submission date |
Mar 01, 2013 |
| Last update date |
Sep 11, 2013 |
| Contact name |
Jonathan Moggs |
| E-mail(s) |
[email protected]
|
| Organization name |
Novartis
|
| Street address |
Fabrikstrasse 2
|
| City |
Basel |
| ZIP/Postal code |
4056 |
| Country |
Switzerland |
| |
|
| Platform ID |
GPL1261 |
| Series (2) |
| GSE44783 |
Expression data from CD-1 mouse liver samples obtained from in-vivo treatment with genotoxic carcinogens, non-genotoxic carcinogens or non-hepatocarcinogens. |
| GSE68387 |
IMI MARCAR Project: towards novel biomarkers for cancer risk assessment |
|
